SecBot SecBot
SECBOTREPLAY Home › Report › NBIX

NBIX · Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up…

NEUROCRINE BIOSCIENCES INC · 8-K filed Nov 2, 2026 at 16:11 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 2, 2026 at 16:11 ET

Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up 41% YoY, with net product sales exceeding $1B for the first time. INGREZZA net sales guidance was raised to $2.9B-$2.925B from $2.825B-$2.875B. Non-GAAP EPS of $3.29 beat the $2.75 consensus, and revenue of $1.123B beat the $1.04B consensus.

  • Q3 2026 total revenue $1.123B, up 41% YoY from $795M
  • INGREZZA net product sales $801M, up 17% YoY
  • CRENESSITY net product sales $211M, up 115% YoY
  • VYKAT XR net product sales $107M (first contribution from Soleno acquisition)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access